Paul S. Herendeen
- Shareholder represented: FF Hybrid LP, Flat Footed Series LLC-Fund3, GP Recovery Fund LLC, Mason Capital Master Fund, L.P. and Sachem Head LP
- Position: Director
- Type: Proprietary
- First appointment: 09/12/24 by co-option
- Appointment date: 05/06/2025, appointed by the shareholders FF Hybrid LP, Flat Footed Series LLC-Fund3, GP Recovery Fund LLC, Mason Capital Master Fund, L.P., and Sachem Head LP, who have appointed him in exercise of their right to proportional representation, grouping 35,887,742 shares, representing 8.42% of the share capital with voting rights.
Mr. Paul S. Herendeen is the Chairman of Endo, Inc. and a Board member of Elanco Animal Health, Inc.
He served as Advisor to the Chairman & Chief Executive Officer at Bausch Health Companies, Inc. Prior to that he was Executive Vice President and Chief Financial Officer of several healthcare companies including Bausch Health, Zoetis Inc., Warner Chilcott plc and MedPointe Inc.
Mr. Herendeen also has several years of experience in finance, investment banking and public accounting. He worked as a principal investor at Dominion Income Management and Cornerstone Partners, in various banking positions with Oppenheimer & Co. and Continental Bank and, in the early part of his career, as a senior auditor at Arthur Andersen & Co.
On the academic side, he holds a bachelor's degree from Boston College and earned a MBA from the University of Virginia's Darden School of Business.